Introduction {#sec1}
============

Male gametogenesis is a process by which spermatogonial stem cells (SSCs) divide and differentiate into haploid spermatids. Any error during male gametogenesis can result in male infertility, which is a major health problem around the world ([@bib7]). Infertility affects around 15% of couples, and male factors account for 50% ([@bib41]). Azoospermia has been observed in 1% of the general populations and accounts for 10%--15% of male infertility ([@bib20; @bib51]). Nonobstructive azoospermia (NOA) affects 10% of infertile men, and notably it has been diagnosed in 60% of azoospermic men ([@bib20; @bib27]). Cryptorchidism is one of the most common causes that result in NOA ([@bib42]). Severe cryptorchidism could lead to male infertility, since male germ cells (especially haploid spermatids) are significantly reduced or completely lost in cryptorchid testes ([@bib56]). It has been reported that the transition of gonocytes into A~dark~ spermatogonia in cryptorchid testes is impaired ([@bib21]). Therefore, it is of great significance to establish an effective method to induce differentiation of human spermatogonia from cryptorchid testes into haploid spermatids for the treatment of male infertility. Previous studies have been focused on the in vitro models of male germ cell maturation ([@bib46]). However, there is currently no efficient approach for generating haploid spermatids in vitro from spermatogonia of human testes.

Complete spermatogenesis in vitro to obtain male gametes has not yet been achieved in humans, although certain progress has been made in the derivation of male germ cells from mouse or human embryonic stem cells (ESCs) ([@bib1; @bib3; @bib6; @bib17; @bib22; @bib28; @bib30; @bib47; @bib49]). There are ethical issues obtaining human ESCs, which is a major obstacle for their potential use in the clinic. It has recently been demonstrated that the induced pluripotent stem cells (iPSCs) could generate primordial germ cells and finally haploid spermatids ([@bib8; @bib14; @bib19; @bib34]). Of great concern, male germ cells derived from human iPSCs may not be used for treating male infertility due to tumor-forming risks, which result from the reprogramming of somatic cells by gene transfer using viral vectors and their genetic instability. Therefore, more attention has been paid to generating male gametes from human spermatogonia of patients.

It has been suggested that several growth factors, such as bone morphogenetic proteins (BMPs), glia cell line-derived neurotrophic factor (GDNF), stem cell factor (SCF), and retinoic acid (RA), were crucial for the maintenance of normal spermatogenesis in rodents. The SCF/KIT system plays an essential role in spermatogonial proliferation, differentiation, survival, and subsequent entry into meiosis ([@bib29]), and SCF has been shown to induce mouse spermatogonia to differentiate into round spermatids in vitro ([@bib10]). Furthermore, SCF is required for the proliferation of mouse differentiating spermatogonia, specifically type A~1~ to A~4~ spermatogonia ([@bib13; @bib44]). RA, the active derivative of vitamin A, controls the entry of germ cells into meiosis in both mice and humans ([@bib4; @bib32]). Interestingly, RA could induce the transition of undifferentiated spermatogonia to differentiating spermatogonia and mediates the timing of meiosis by the activation of the SCF/KIT pathway ([@bib35; @bib55]). Therefore, RA and SCF were chosen in this study to induce the differentiation of human spermatogonia from cryptorchid testes. It has been recently reported by our peers and us that human SSCs can be clearly identified and cultured for a short- and long-term period ([@bib15; @bib40; @bib39]). Round spermatids with unknown function can be derived from mouse spermatogonia ([@bib11]). Nevertheless, the generation of functional haploid spermatids from SSCs in vitro has not yet been achieved in humans. Here, we present molecular and cellular evidence demonstrating the differentiation of human SSCs from cryptorchid patient into cells with phenotypic characteristics, DNA content, and fertilization and development capacity of haploid spermatids. Of unusual significance, our ability to generate human functional haploid spermatids from cryptorchid testes could offer an important source of functional and autologous male gametes for treating male infertility in azoospermia patients.

Results {#sec2}
=======

Cryptorchid Patients Had a Normal Karyotype and Excluded Y Chromosome Microdeletion or Gene Mutation {#sec2.1}
----------------------------------------------------------------------------------------------------

We first checked the chromosome karyotype and the expression of numerous Y chromosome genes of cryptorchid patients. Karyotype analysis revealed that cryptorchid patients possessed a normal chromosome karyotype ([Figure 1](#fig1){ref-type="fig"}A). Multiplex PCR was used to check whether cryptorchid patients had Y chromosome microdeletion. As shown in [Figure 1](#fig1){ref-type="fig"}C, numerous Y chromosome genes, including *SRY*, *sY254*, *sY127*, *sY86*, *sY134*, *sY84*, and *sY255*, were detected in cryptorchid patients, which was comparable to the expression of these genes in normal men ([Figure 1](#fig1){ref-type="fig"}B), suggesting that cryptorchid patients did not have Y chromosome microdeletion. Mutation analyses using gene sequencing were performed to screen the mutation of *INSL3* (insulin-like 3), *RXFP2* (relaxin/insulin-like family peptide receptor 2), and *AR* (androgen receptor) genes in cryptorchid patients and normal men, and no mutation of those genes was observed (data not shown). Therefore, testicular tissues of these cryptorchid patients were used to induce differentiation.

The clinic data of cryptorchid patients are shown in [Table S1](#app3){ref-type="sec"} (available online). The levels of testosterone (T) and estradiol (E2) of cryptorchid patients were within the normal ranges. However, both left and right testicular volumes of cryptorchid patients were significantly smaller than those of normal men. The levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin (PRL) in cryptorchid patients were statistically higher than those of normal men.

Human SSCs Remained whereas Meiotic Male Germ Cells Were Very Rare or Lost in the Testes of Cryptorchid Patients {#sec2.2}
----------------------------------------------------------------------------------------------------------------

Histological and immunohistochemical analyses of cryptorchid patients were performed to evaluate the spermatogenesis status of testicular tissues. The testes from obstructive azoospermia (OA) patients due to inflammation but with normal spermatogenesis in vivo served as the controls. Histological examination showed that seminiferous tubules of cryptorchid testes had a reduced tubular diameter and a thickened basement membrane ([Figure 2](#fig2){ref-type="fig"}B) compared to the control testes ([Figure 2](#fig2){ref-type="fig"}A). There were human spermatogonia along the basement membrane in cryptorchid testes ([Figure 2](#fig2){ref-type="fig"}B); however, differentiated male germ cells, including spermatocytes and haploid spermatids, were very rare or completely lost in the seminiferous tubules of cryptorchid testes ([Figure 2](#fig2){ref-type="fig"}B) compared with the control testes ([Figure 2](#fig2){ref-type="fig"}A).

Immunohistochemistry of MAGEA4 (melanoma antigen family A, 4), a marker for human spermatogonia ([@bib15]), revealed that the number of spermatogonia was diminished in cryptorchid testes ([Figure 2](#fig2){ref-type="fig"}D) compared to the control testes ([Figure 2](#fig2){ref-type="fig"}C). To verify specific staining of MAGEA4, replacement of primary antibody with normal mouse immunoglobulin G (IgG) was used as a negative control, and no positive reaction was seen in normal testes ([Figure 2](#fig2){ref-type="fig"}E) or the testes of cryptorchid patients ([Figure 2](#fig2){ref-type="fig"}F). The seminiferous tubules of cryptorchid testis were also characterized by immunostaining with SCP3 (synaptonemal complex protein 3), a specific marker for meiotic germ cells ([@bib48]). Immunohistochemistry showed that very few cells were positive for SCP3 in the seminiferous tubules of cryptorchid testis ([Figure 2](#fig2){ref-type="fig"}H) compared to the control testes ([Figure 2](#fig2){ref-type="fig"}G). Replacement of primary antibody with normal rabbit IgG and PBS served as a negative control, and no staining was observed in normal testes ([Figure 2](#fig2){ref-type="fig"}I and data not shown) or the testes of cryptorchid patients ([Figure 2](#fig2){ref-type="fig"}J and data not shown), which confirmed the specific staining of SCP3. Taken together, these results reflect that spermatogonia remained whereas meiotic male germ cells were rare or lost in the testes of cryptorchid patients.

Generation of Spermatocytes and Haploid Spermatids In Vitro from Human SSCs of Cryptorchid Patients {#sec2.3}
---------------------------------------------------------------------------------------------------

Human male germ cells were isolated from testis tissues of 16 cryptorchid patients and 9 OA patients using two-step enzymatic digestion followed by differential plating ([Figure 3](#fig3){ref-type="fig"}A). Notably, immunocytochemistry showed that almost all of the freshly isolated male germ cells from cryptorchid patients were strongly positive for UCHL1 ([Figure 3](#fig3){ref-type="fig"}E) and GFRA1 ([Figure 3](#fig3){ref-type="fig"}F). Replacement of primary antibodies with PBS or normal IgG served as a negative control, and no staining was observed (data not shown). UCHL1 has been considered a marker for human spermatogonia, while GFRA1 is regarded as a hallmark for human SSCs ([@bib15]). Collectively, these data suggest that the freshly isolated male germ cells were phenotypically human SSCs.

RA and SCF have been reported to play important roles in promoting spermatogenesis in rodents, and thus they were utilized to induce the differentiation of human SSCs from cryptorchid patients. After 7 days of culture, the isolated human male germ cells were able to proliferate and form colonies of ∼10--50 cells ([Figure 3](#fig3){ref-type="fig"}B). The cells in these colonies were human SSCs with proliferation potential ([@bib15; @bib40; @bib39]), and they were treated without or with RA and SCF for differentiation. Various concentrations of SCF, ranging from 20 ng/ml to 150 ng/ml, were used to optimize the condition for inducing differentiation of human SSCs. RT-PCR assays showed that the expression of *SYCP3* ([Figure S1](#app3){ref-type="sec"}A) and *ACR* (acrosin) ([Figure S1](#app3){ref-type="sec"}B) was the highest in human SSCs treated with 100 ng/ml SCF compared to other concentrations of SCF, and thus 100 ng/ml SCF was used to coax the differentiation of human SSCs. Morphological analysis revealed a different pattern of human SSCs without or with RA and SCF treatment. Interestingly, more male germ cells became enlarged in human SSCs treated with RA and SCF ([Figure 3](#fig3){ref-type="fig"}D) compared to the control group without RA or SCF ([Figure 3](#fig3){ref-type="fig"}C). Considered together, these data suggest RA and SCF induce both proliferation and differentiation of human SSCs.

We next evaluated the differentiation potential of human SSCs from cryptorchid patients. Real-time RT-PCR revealed that the transcripts of *SYCP1*, *SYCP3*, *ACR*, and *TNP1* (transition protein 1), hallmarks of meiotic germ cells and haploid germ cells, respectively ([@bib48]), were significantly upregulated in cryptorchid patient SSCs with RA and SCF treatment compared to the freshly isolated cells or the control without SCF and RA ([Figure 3](#fig3){ref-type="fig"}G). Likewise, the expression of *SYCP1*, *SYCP3*, *ACR*, and *DMC1* (DNA meiotic recombinase 1), was remarkably enhanced in human SSCs of OA patients with RA and SCF treatment compared to the control without SCF and RA or the freshly isolated cells ([Figure 3](#fig3){ref-type="fig"}H). In addition, RT-PCR and real-time PCR reflected that transcripts of *SYCP1*, *SYCP2*, *SYCP3*, *BOULE*, *PRM1* (protamine 1), *PRM2* (protamine 2), *TNP1*, *TNP2* (transition protein 2), and *ACR*, markers of meiotic cells and haploid spermatids, respectively ([@bib24; @bib48]), were significantly increased in human SSCs of cryptorchid patients with RA and SCF treatment compared to the control without SCF or RA treatment ([Figures S2](#app3){ref-type="sec"}A--S2D), while mRNA levels of *SYCP2*, *TNP1*, *TNP2*, and *PRM2* were also enhanced in human SSCs of OA patients with RA and SCF treatment compared to the control without SCF or RA ([Figure S2](#app3){ref-type="sec"}E). These results suggest that RA and SCF induce the differentiation of human SSCs from cryptorchid patients and OA patients into meiotic male germ cells and haploid cells at transcriptional levels.

To determine whether RA and SCF could initiate the meiosis stage of male germ cells, meiotic progression was performed by examining the expression of SCP3, CREST, and MLH1, specific markers for meiosis ([@bib23; @bib33]). Meiotic spreads of human SSCs without or with SCF and RA treatment from cryptorchid patients and OA patients were analyzed by immunostaining with antibodies against SCP3 for detecting axial/lateral elements of the synaptonemal complex, MLH1 for measuring the meiotic recombination frequency, and CREST for determining centromeric regions ([@bib16]). Notably, RA and SCF induced a significantly higher percentage of SCP3-, CREST-, and MLH1-positive cells compared to human SSCs without RA or SCF treatment in cryptorchid patients ([Figure 4](#fig4){ref-type="fig"}A and 4D) and OA patients ([Figure 4](#fig4){ref-type="fig"}B and 4E). Meiotic spreads of SCP3, CREST, and MLH1 in pachytene spermatocytes from OA and NOA patients served as positive controls ([Figure 4](#fig4){ref-type="fig"}C). Together, these data indicate that RA and SCF promote the differentiation of human SSCs of from cryptorchid patients and OA patients into various meiotic stages of male germ cells.

Protamine 2 and acrosin are generally regarded as markers for haploid cells. Immunocytochemistry further revealed that protamine 2-positive cells were enhanced in human SSCs with RA and SCF treatment ([Figure S3](#app3){ref-type="sec"}B) compared to the control ([Figure S3](#app3){ref-type="sec"}A). Moreover, acrosin-positive cells were remarkably increased in human SSCs with RA and SCF treatment ([Figures S3](#app3){ref-type="sec"}D and S3E) compared to the control ([Figures S3](#app3){ref-type="sec"}C and S3E). The developmental stages of differentiated cells from human SSCs treated with SCF and RA were shown by expression of acrosin ([Figure 5](#fig5){ref-type="fig"}A) and protamine 2 ([Figure 5](#fig5){ref-type="fig"}B). Considered together, these results implicate that RA and SCF stimulate the differentiation of human SSCs into haploid spermatids.

RA and SCF Induced a Notable Increase of Haploid Cell Population of Cryptorchid Patients {#sec2.4}
----------------------------------------------------------------------------------------

To compare the ploidy levels of human SSCs with or without RA and SCF treatment, DNA contents were analyzed by flow cytometry. Notably, haploid cells were increased from 7.4% to 15.03% in human SSCs from cryptorchid patients ([Figure 5](#fig5){ref-type="fig"}C) with RA and SCF treatment compared to the control. Cell sorting of haploid cells derived from cryptorchid patients' SSCs was performed using Hoechst 33342, and immunocytochemistry revealed that over 99% of these cells were positive for acrosin ([Figure 5](#fig5){ref-type="fig"}D). These data further suggest that RA and SCF promote the differentiation of human SSCs into haploid spermatids.

Human Round Spermatids Generated from Human SSCs of Cryptorchid Patients and OA Patients Could Fertilize Mouse Oocytes to Form Embryos with Developmental Potentials {#sec2.5}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

Round spermatid microinjection (ROSI) was performed to determine the fertilization capacity of human round spermatids generated from human SSCs of cryptorchid patients and OA patients. The ROSI procedure is shown in [Figure S4](#app3){ref-type="sec"}. Among the microinjection of human 60 round spermatids derived from cryptorchid patients, 60% of them could fertilize mouse oocytes and survived to form embryos with two pronuclei ([Figure 6](#fig6){ref-type="fig"}A; [Table S2](#app3){ref-type="sec"}). Notably, 61% of the embryos had the potential to develop to the two-cell stage ([Figure 6](#fig6){ref-type="fig"}B; [Table S2](#app3){ref-type="sec"}), and 16.7% and 5.6% of the embryos could develop to four-cell ([Figure 6](#fig6){ref-type="fig"}C; [Table S2](#app3){ref-type="sec"}) and eight-cell stages ([Figure 6](#fig6){ref-type="fig"}D; [Table S2](#app3){ref-type="sec"}), respectively.

To verify the fertilization of human round spermatids generated from human SSCs of cryptorchid patients with mouse oocytes and exclude parthenogenetic activation of mouse oocytes themselves, immunocytochemistry was carried out using human antibody against HumNuc. The embryos derived from mouse oocytes fertilized with human round spermatids of cryptorchid patients were positive for human anti-HumNuc ([Figure 6](#fig6){ref-type="fig"}E). Replacement of human anti-HumNuc with normal rabbit IgG ([Figure 6](#fig6){ref-type="fig"}F) or PBS ([Figure 6](#fig6){ref-type="fig"}G) in the embryos developed from mouse oocytes fertilized with human round spermatids served as a negative control, and no staining was seen.

Moreover, single-cell RNA sequencing analysis revealed that there were 26,186,786 total reads and 18,722,732 total mapped reads in the embryos derived from round spermatids, while 24,676,032 total reads and 13,036,264 total mapped reads were detected in the embryos generated from the nucleus of Sertoli cells. We identified 9,385 genes in the embryos derived from round spermatids and the nucleus of Sertoli cells ([Figure S5](#app3){ref-type="sec"}A), and there were 5,699 differentially expressed genes (DEGs) ([Figure 6](#fig6){ref-type="fig"}H; [Figure S5](#app3){ref-type="sec"}B) and distinct distribution of gene coverage ([Figure S5](#app3){ref-type="sec"}C) between the embryos from round spermatids and the nucleus of Sertoli cells. Functional analysis of these DEGs reflected three major types and numerous subtypes of roles ([Figure S5](#app3){ref-type="sec"}D).

To further observe the dynamic changes during embryo development, H3K9 trimethylation (H3K9-TriM) was applied to label the maternal genomes. As shown in [Figure S6](#app3){ref-type="sec"}, maternal pronuclei were positive for H3K9-TriM, while its staining in male pronucleus was hardly detectable in each group. Sperm chromatin began to decondense immediately after fertilization ([Figures S6](#app3){ref-type="sec"}A and S6B), and male and female pronuclei formed at 4 hr and 6 hr after fertilization ([Figures S6](#app3){ref-type="sec"}C and S6D). At the two-cell stage, both nuclei of embryos stained positively for H3K9-TriM ([Figure S6](#app3){ref-type="sec"}E). Interestingly, the embryos derived from round spermatids showed a different distribution pattern of H3K9-TriM compared to embryos derived from PBS ([Figure S6](#app3){ref-type="sec"}F) or from the nucleus of Sertoli cells with both pseudopronuclei and female pronuclei ([Figure S6](#app3){ref-type="sec"}G). Collectively, these results clearly implicate that human round spermatids derived from human SSCs of cryptorchid patients have both fertilization and development potential.

Discussion {#sec3}
==========

We highlight the generation of human functional haploid spermatids from human SSCs of cryptorchid patients. Cryptorchidism is the most common etiologic factor for azoospermia in adults. Among men with untreated bilateral cryptorchidism, 89% eventually develop azoospermia ([@bib5]). However, the exact causes of most cases of cryptorchidism remain unknown ([@bib36]). Our data indicate that cryptorchid patients have a normal chromosome karyotype with no mutations of *INSL3*, *RXFP2*, and *AR* genes. It has been suggested that a reduced total number of male germ cells in cryptorchid testes is the cause of male infertility ([@bib12]). Therefore, in vitro differentiation of human SSCs into haploid spermatids from cryptorchid testes could be an ideal method for treating infertility in cryptorchid patients. Here, we have shown obvious evidence for rescuing germ cell development in cryptorchid patients using in vitro techniques, as evidenced by our finding that human SSCs from cryptorchid patients can progressively differentiate into meiotic and haploid spermatids by treatment with RA and SCF.

We first evaluated the spermatogenesis status of cryptorchid patients using immunohistochemistry with MAGEA4 and SCP3. Notably, human spermatogonia exist whereas meiotic male germ cells are rather rare or completely lost in the testis of cryptorchid patients, since there were numerous cells positive for MAGEA4, a marker for human spermatogonia ([@bib15]), whereas fewer cells stained positively for SCP3, a hallmark for spermatocytes ([@bib48]). This conclusion can also be verified by our observations that almost all freshly isolated male germ cells from cryptorchid patients were positive for UCHL1, a marker for human spermatogonia ([@bib15]), and GFRA1, a surface hallmark for human SSCs ([@bib15]). Our results are consistent with previous findings showing defective maturation of germ cells in cryptorchid patients ([@bib2; @bib18]).

Using multiplex PCR, we found that a number of Y chromosome genes, including *SRY*, *sY254*, *sY127*, *sY86*, *sY134*, *sY84*, and *sY255*, were present in cryptorchid patients, thus excluding Y chromosome microdeletion in cryptorchid patients. Therefore, testis tissues of these cryptorchid patients were chosen for differentiating into spermatocytes and haploid spermatids.

The starting cells we used for differentiation were colony cells. We found that isolated cells from cryptorchid testes were able to proliferate and form colonies composed of numerous cells. We and others have revealed that the cells in these colonies were SSCs with proliferation potential ([@bib15; @bib39]). It has been demonstrated by xenotransplantation that the cells in the colonies were actually human SSCs with self-renewal capacity ([@bib39]). The differentiation potential of human SSCs from cryptorchid testes was assessed by various types of approaches, including quantitative PCR, RT-PCR, immunocytochemistry, and meiotic spread assays. After treatment with RA and SCF, the expression of numerous genes for meiotic and haploid cells, including *SYCP1*, *SYCP2*, *SYCP3*, *BOULE*, *PRM1*, *PRM2*, *TNP1*, *TNP2*, and *ACR* ([@bib16; @bib45; @bib48]), in human SSCs was obviously enhanced. SCP3 can be used to measure the synaptonemal complex, while CREST is a hallmark for detecting centromeric regions and MLH1 has been utilized for measuring meiotic recombination frequency ([@bib16]). Our results, using these markers for meiosis and postmeiosis, clearly indicate that RA and SCF could induce human spermatogonia to enter the postmeiotic stage and eventually differentiate into haploid spermatids. RA has been shown to play an important role in triggering germ cells to enter meiosis ([@bib31]). We have previously reported that RA can act as a meiosis-inducing factor in the differentiation of iPSCs into male germ cells ([@bib53]). SCF has been shown to be essential in spermatogonial differentiation as well as meiotic initiation ([@bib10]). The SCF/KIT interaction plays a critical role in meiotic entry of differentiating spermatogonia ([@bib38]). Furthermore, the crosstalk between RA and the SCF pathway could stimulate differentiation of male germ cells toward the meiotic stages ([@bib35]). Consistent with these findings, we found that RA and SCF could efficiently induce the differentiation of human SSCs from cryptorchid testes into postmeiotic male germ cells.

We further explored the ploidy levels of human SSCs with RA and SCF treatment by detecting DNA content. Notably, the percentage of haploid cells was significantly increased in human SSCs by RA and SCF treatment, although spontaneous differentiation of SSCs into haploid cells was observed in control samples without RA or SCF induction. As such, RA and SCF promote the differentiation of human SSCs into haploid spermatids. The SCF/KIT signaling pathway has been proven to be essential for human ESCs to differentiate into human germ cells ([@bib50]). Additionally, RA has a crucial role in pushing complete meiosis and generating haploid cells from mouse ESCs and human iPSCs ([@bib9; @bib30; @bib37]). Taken together, these studies from our peers and us suggest that RA and SCF are effective to coax the second meiosis of germ cells into haploid spermatids. It remains unknown whether round spermatids derived from mouse spermatogonia have fertilization ability ([@bib11]). Of unusual significance, haploid spermatids generated from human SSCs of cryptorchid patients had the potential to fertilize oocytes to form embryos that were capable of developing into eight-cell stages.

In summary, we have demonstrated that RA and SCF are effective in promoting the differentiation of human SSCs from cryptorchid patients into cells with phenotypic features, DNA content, and fertilization and development capacity of haploid spermatids. This study thus offers an approach to generate human functional haploid spermatids from cryptorchid testes, which could provide autologous male gametes for clinical treatment of infertile cryptorchid patients using assisted reproductive technology.

Experimental Procedures {#sec4}
=======================

Procurement of Testicular Biopsy Specimens from Cryptorchid Patients and Obstructive Azoospermia Patients {#sec4.1}
---------------------------------------------------------------------------------------------------------

Testicular biopsy specimens were obtained from 16 cryptorchid patients and 9 obstructive azoospermia (OA) patients 13 to 47 years of age (28.93 ± 2.25 years) from January 2012 to June 2014. Cryptorchid patients were selected by excluding abnormal karyotype; Y chromosome microdeletion; gene mutation of *INSL3*, *RXFP2*, and *AR*; and Sertoli cell-only syndrome. Clinical data of cryptorchid patients are shown in [Table S1](#app3){ref-type="sec"}. OA patients with normal spermatogenesis in vivo were used as controls. All OA was caused by inflammation and vasoligation, but not by congenital absence of the vas deferens or other diseases including cancer. This study was approved by the institutional ethical review committee of Ren Ji Hospital (license number of ethics statement: 2012-01), Shanghai Jiao Tong University School of Medicine. The collected testis tissues were immediately placed aseptically in Dulbecco's modified Eagle's medium (DMEM) containing penicillin and streptomycin (Gibco).

Karyotype Analysis {#sec4.2}
------------------

Chromosomal karyotype analysis of peripheral blood lymphocytes from cryptorchid patients was performed, and the karyotypes were interpreted using the recommendation of the International System for Human Cytogenetic Nomenclature.

Multiplex PCR {#sec4.3}
-------------

Peripheral venous blood was obtained from cryptorchid patients and normal men. Multiplex PCR was performed to check the expression of numerous Y chromosome genes, including *SRY*, *sY254*, *sY127*, *sY86*, *sY134*, *sY84*, and *sY255*, according to a procedure we described previously ([@bib26]). The primers of chosen genes were shown previously ([@bib43]), and PCR without primers served as negative controls.

Histological Examination {#sec4.4}
------------------------

Testicular tissues from cryptorchid patients and OA patients were fixed in 4% paraformaldehyde for 3 hr or in Bouin's fixative overnight, embedded in paraffin, and sectioned at 5 μm thickness. The sections were stained with hematoxylin and eosin (H&E) and observed under a microscope.

Isolation and Culture of Male Germ Cells from Cryptorchid Patients {#sec4.5}
------------------------------------------------------------------

The seminiferous tubules were isolated from testicular tissues of 16 cryptorchid patients and nine OA patients using the first enzymatic digestion including collagenase IV (Sigma) and DNase I using a procedure previously described ([@bib15]). Human testicular cells were obtained using a second enzymatic digestion with collagenase IV, hyaluronidase (Sigma), trypsin (Sigma), and DNase I and followed by differential plating to remove human Sertoli cells using a procedure previously described ([@bib15]). For differential plating, cell suspensions were seeded into culture plates in DMEM/F-12 (Gibco) supplemented with 10% fetal bovine serum (FBS; Hyclone) and incubated at 34°C in 5% CO~2~ for 3 hr. After incubation, Sertoli cells attached to culture plates, while male germ cells were suspended and collected by centrifuge. Male germ cells were cultured in DMEM/F12 containing 10% FBS, 2 μM RA (Sigma), and 20--150 ng/ml SCF (Peprotech) for 7 to 10 days. The cells cultured with DMEM/F12 and 10% FBS but without RA or SCF were used as controls. All cultures were maintained at 34°C in a humidified 5% CO~2~ incubator.

Meiotic Spread Assays {#sec4.6}
---------------------

Meiotic spread assays were performed to determine the meiotic progression in human SSCs of cryptorchid patients and OA patients without or with RA and SCF treatment as well as in pachytene spermatocytes of OA and NOA patients according to a method described previously ([@bib33]). Briefly, cells were lysed by a hypotonic solution and spread evenly over slides layered with 1% paraformaldehyde (PFA) and 0.15% Triton X-100. Slides were dried for 24 hr at room temperature in a humid chamber. The cells were treated with 0.04% photoflo for 5 min and blocked with 4% goat serum. Triple staining was performed in cells incubated with primary antibodies, including rabbit polyclonal to SCP3 (Abcam), human anti-centromere (CREST) (Immunovision), and mouse MLH1 monoclonal antibody (Abcam), overnight at 37°C in a humid chamber. Goat anti-rabbit Alexa Fluor 555 (Invitrogen), AMCA-AffiniPure donkey anti-human IgG, and goat anti-mouse Alexa 488 secondary antibodies (Jackson) were applied at 1:1,000 dilution and incubated for 90 min at 37°C. Cells were washed three times with PBS, and images were captured with a fluorescence microscope (Leica).

Flow Cytometry and Isolation of 1N Haploid Cells {#sec4.7}
------------------------------------------------

Flow cytometry was performed to measure DNA content of human SSCs of cryptorchid patients and OA patients without or with RA and SCF treatment. In brief, cells were washed twice in PBS and fixed in cold 70% ethanol. After being stained in a solution containing 25 μg/ml propidium iodide (PI) (Sigma), 40 μg/ml RNase (Invitrogen), and 0.3% Tween-20 in PBS at room temperature for 20 min, cells were analyzed with a FACSCalibur system (Becton Dickinson).

To isolate 1N haploid cells, cells was stained with 10 μg/ml Hoechst 33342 (Sigma) in culture medium at 34°C for 60 min. The haploid 1N peak was collected and fixed with 4% PFA before immunostaining.

ROSI Derived from Human SSCs of Cryptorchid and OA Patients into Mouse Oocytes {#sec4.8}
------------------------------------------------------------------------------

Microinjection of round spermatids (ROSI) was performed to detect the fertilization capacity of round spermatids derived from human SSCs of cryptorchid and OA patients using a procedure described previously ([@bib25]). Female B6D2F1 mice were superovulated by the injection of 5 IU equine chorionic gonadotropin followed by 5 IU human chorionic gonadotropin (hCG) 48 hr later. Cumulus-oocyte complexes were collected from oviducts at 14--16 hr after hCG injection, and they were placed in HEPES Chatot-Ziomek-Bavister (CZB) medium and treated with 0.1% hyaluronidase to disperse cumulus cells. The oocytes were washed twice and then moved to a new 20 μl CZB drop for culture. Oocytes were incubated for at least 15 min after collection in plain CZB media, and they were placed into Ca^2+^-free CZB containing 10 mM SrCl~2~ for 1 hr in order to activate the oocytes artificially. After being washed twice, oocytes were transferred to CZB medium to resume incubation. Human round spermatids were collected from fresh testicular cells of obstructive azoospermia patients or human SSCs of cryptorchid patients with RA and SCF treatment. Round spermatids can easily be recognized by their small size and the presence of a round nucleus with a centrally located nucleolus ([@bib54]). Human Sertoli cells were isolated from OA patients using a two-step enzymatic digestion and differential plating according to a procedure described previously ([@bib15]). ROSI was performed using a micromanipulator with piezoelectric elements, and injection of the nucleus of human Sertoli cells or PBS into oocytes served as controls. The oocytes fertilized with human round spermatids from cryptorchid patients and OA patients were incubated in CZB medium at 37°C under 5% CO~2~ in air to examine pronucleus formation and in vitro development.

Single-Cell RNA Sequencing Analysis of Embryos Derived from Round Spermatids of Cryptorchid Patients and the Nucleus of Sertoli Cells {#sec4.9}
-------------------------------------------------------------------------------------------------------------------------------------

To compare global gene expression, single-cell RNA sequencing analysis of embryos derived from round spermatids of cryptorchid patients and the nucleus of Sertoli cells was performed according to a procedure described previously ([@bib52]). Briefly, single blastomeres were isolated from embryos derived from the microinjection of round spermatids or the nucleus of Sertoli cells to mouse oocytes after removing the zona pellucida using acidic Tyrode solution (Sigma), and total RNA was extracted from the blastomeres using lysate buffer and mRNA was enriched by Oligo(dT) and followed by mRNA fragment. The cDNA was synthesized by using random hexamer-primer and dinucleotide triphosphates and size selected, and PCR amplification was performed. Agilent 2100 Bioanaylzer and ABI StepOnePlus Real-Time PCR System were used to qualify and quantify of the sample library. The library products were used for Illumina sequencing (Beijing Genomics Institute, Shenzhen, China).

Statistical Analysis {#sec4.10}
--------------------

All data are presented as mean ± SEM. Experiments with samples from three patients were performed three times unless otherwise stated, and the number of independent experiments performed is given as "n" in the figure legends. Statistical analyses were performed using Student's t test, and p \< 0.05 was considered statistically significant.

Accession Numbers {#app1}
=================

Sequence data for the sequences of embryos derived from round spermatids of human SSCs and the nucleus of human Sertoli cells reported in this paper have been deposited to the NCBI Sequence Read Archive (SRA) under accession number [SRP044280](ncbi-geo:SRP044280){#intref0010}.
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![Karyotype and the Completeness of Genomic DNA Sequence of Numerous Y Chromosome Genes in Cryptorchid Patients\
(A) Karyotype analysis displaying chromosome karyotype in cryptorchid patients.\
(B and C) Multiplex PCR showing the expression of numerous Y chromosome genes, including *SRY*, *sY254*, *sY127*, *sY86*, *sY134*, *sY84*, and *sY255*, in a normal man (B) and in a cryptorchid patient (C).\
See also [Table S1](#app3){ref-type="sec"}.](gr1){#fig1}

![Morphology and MAGEA4 and SCP3 Expression in the Testes of Cryptorchid Patients and OA Patients\
(A and B) H&E staining showing the morphology of testicular tissues from OA patients (A) and cryptorchid patients (B). Scale bar in (A), 20 μm, and scale bar in (B), 50 μm.\
(C and D) Immunohistochemistry revealing MAGEA4 expression in testis sections from OA patients (C) and cryptorchid patients (D). Scale bars in (C) and (D), 50 μm.\
(E and F) Replacement of anti-MAGEA4 by normal mouse IgG in testis sections of OA patients (E) and cryptorchid patients (F) served as negative controls. Scale bars in (E) and (F), 70 μm.\
(G and H) Immunohistochemistry revealing SCP3 expression in testis sections from OA patients (G) and cryptorchid patients (H). Scale bars in (G) and (H), 30 μm.\
(I and J) Replacement of anti-SCP3 by normal rabbit IgG in testis sections from OA patients (I) and cryptorchid patients (J) was used as negative controls. Scale bars in (I) and (J), 30 μm.](gr2){#fig2}

![Morphological and Phenotypic Characteristics of Human SSCs without or with SCF and RA Treatment as well as UCHL1 and GFRA1 Expression in the Freshly Isolated Germ Cells\
(A--D) Phase-contrast microscopy showing the morphology of the freshly isolated germ cells (A) and human SSCs with SCF and RA treatment (B and D) or without RA and SCF treatment (C). Scale bars in (A) and (B), 50 μm, and scale bars in (C) and (D), 25 μm.\
(E and F) Immunocytochemistry revealing the expression of UCHL1 (E) and GFRA1 (F) in the freshly isolated male germ cells from cryptorchid patients. Scale bars in (E) and (F), 10 μm.\
(G) Real-time RT-PCR displaying the transcripts of *SYCP1* (12.63 ± 0.65, n = 3), *SYCP3* (12.20 ± 0.21, n = 3), *ACR* (10.72 ± 0.16, n = 3), and *TNP1* (1.18 ± 0.005, n = 3) in cryptorchid patient SSCs with SCF and RA treatment, as well as the expression of *SYCP1* (0.78 ± 0.011, n = 3), *SYCP3* (0.88 ± 0.01, n = 3), *ACR* (0.78 ± 0.02, n = 3), and *TNP1* (0.91 ± 0.001, n = 3) in cryptorchid patient SSCs without SCF and RA treatment (control). The expression of *SYCP1* (1.00 ± 0.04, n = 3), *SYCP3* (1.00 ± 0.11, n = 3), *ACR* (1.00 ± 0.01, n = 3), and *TNP1* (1.00 ± 0.01, n = 3) in freshly isolated male germ cells from cryptorchid patients is also shown.\
(H) Real-time RT-PCR showing the transcripts of *SYCP1* (38.40 ± 0.77, n = 3), *SYCP3* (12.94 ± 0.44, n = 3), *ACR* (17.37 ± 2.57, n = 3), and *TNP1* (7.26 ± 0.21, n = 3) in OA patient SSCs with SCF and RA treatment, as well as the expression of *SYCP1* (31.36 ± 2.61, n = 3), *SYCP3* (6.92 ± 1.30, n = 3), *ACR* (6.23 ± 1.31, n = 3), and *TNP1* (5.07 ± 0.31, n = 3) in OA patient SSCs without SCF and RA treatment (control). The expression of *SYCP1* (1.00 ± 0.01, n = 3), *SYCP3* (1.00 ± 0.07, n = 3), *ACR* (1.00 ± 0.02, n = 3), and *TNP1* (1.00 ± 0.06, n = 3) in freshly isolated male germ cells from patients is displayed.\
*^∗^*p \< 0.05 in RA+SCF-treated cells compared with the control. See also [Figures S1](#app3){ref-type="sec"} and [S2](#app3){ref-type="sec"} and [Table S3](#app3){ref-type="sec"}.](gr3){#fig3}

![Meiotic Progression of Human SSCs without or with SCF and RA Treatment from Cryptorchid Patients and OA Patients\
(A and B) Meiotic spread assays revealing the expression of SCP3 (red fluorescence), CREST (blue fluorescence), and MLH1 (green fluorescence) in human SSCs without or with SCF and RA treatment from cryptorchid patients (A) and OA patients (B). Scale bars in (A) and (B), 10 μm.\
(C) The expression of SCP3 (red fluorescence), CREST (blue fluorescence), and MLH1 (green fluorescence) in pachytene spermatocytes from OA and NOA patients served as positive controls. Scale bar in (C), 10 μm.\
(D) Meiotic spread assays showing the percentage of SCP3-positive cells in human SSCs with SCF and RA treatment (23.41% ± 2.22%, n = 3) and without SCF and RA treatment (control) (14.20% ± 1.29%, n = 3) from cryptorchid patients.\
(E) Meiotic spread assays revealing the percentage of SCP3-positive cells in human SSCs with SCF and RA treatment (27.10% ± 2.69%, n = 3) and without SCF and RA treatment (control) (21.20 ± 0.60%, n = 3) from OA patients.\
*^∗^*p \< 0.05 in RA+SCF-treated cells compared with the control.](gr4){#fig4}

![The Expression of Haploid Markers and DNA Content in Human SSCs without or with SCF and RA Treatment from Cryptorchid Patients\
(A and B) Immunocytochemistry displaying the expression of acrosin (A) and protamine 2 (B) in differentiated cells from human SSCs with SCF and RA treatment. Scale bars in (A) and (B), 10 μm.\
(C) Flow cytometry showing DNA content in the differentiated cells from human SSCs without SCF and RA treatment (7.40% ± 1.77%, n = 3) or with SCF and RA treatment (15.03% ± 1.22%, n = 3) from cryptorchid patients. *^∗^*p \< 0.05 in RA+SCF-treated cells compared with the control.\
(D) Immunocytochemistry showing acrosin expression in the sorted cells of the differentiated cells from cryptorchid patients (upper panel). The expression of acrosin in donated normal human sperm served as positive controls (lower panel). Scale bar in upper panel, 20 μm, and scale bar in lower panel, 50 μm.\
See also [Figure S3](#app3){ref-type="sec"}.](gr5){#fig5}

![Developmental Potentials, HumNuc Expression, and Global Gene Expression Patterns of the Embryos from Mouse Oocytes Fertilized with Round Spermatids Derived from Human SSCs of Cryptorchid Patients\
(A--D) Phase-contrast microscope showing the morphology of embryos with two pronuclei (PN) (A), embryos developing into the two-cell (B), four-cell (C), and eight-cell (D) stages. Scale bars in (A)--(D), 50 μm.\
(E) Immunocytochemistry revealing the expression of HumNuc in the embryos from mouse oocytes fertilized with human round spermatids from human SSCs.\
(F and G) Replacement of HumNuc antibody with normal rabbit IgG (F) or PBS (G) in the embryos from mouse oocytes fertilized with human round spermatids served as negative controls. Scale bars in (E)--(G), 25 μm.\
(H) Clustering of the transcriptome of single embryo derived from round spermatids of cryptorchid patients and from the nucleus of Sertoli cells by single-cell RNA sequencing analysis.\
See also [Figures S4--S6](#app3){ref-type="sec"} and [Table S2](#app3){ref-type="sec"}.](gr6){#fig6}
